(Q37979856)

26 August 2017

Emerging drugs for small cell lung cancer--an update (English)

1 reference

26 August 2017

4

1 reference

26 August 2017

1

Giulio Metro

1 reference

26 August 2017

Simona Duranti

2

1 reference

26 August 2017

Matthias Joachim Fischer

series ordinal

3

1 reference

26 August 2017

Lucio Crinò

series ordinal

5

1 reference

26 August 2017

language of work or name

English

0 references

publication date

31 January 2012

1 reference

Expert Opinion on Emerging Drugs

26 August 2017

1 reference

26 August 2017

17

1 reference

26 August 2017

1

1 reference

26 August 2017

31-36

1 reference

Emerging drugs for small-cell lung cancer

26 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.656588

Role of surgery in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.656588

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.656588

Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.656588

Review of the management of relapsed small-cell lung cancer with amrubicin hydrochloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.656588

Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.656588

Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.656588

Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.656588

Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.656588

Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.656588

Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.656588

Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.656588

Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.656588

Diagnosing and exploiting cancer's addiction to blocks in apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.656588

Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.656588

Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.656588

The Hedgehog's tale: developing strategies for targeting cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.656588

Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.656588

Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.656588

Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.656588

MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.656588

10.1517/14728214.2012.656588

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference